Clozapine is an atypical neuroleptic medication with superior efficacy to conventional antipsychotic agents for patients with chronic, symptomatic schizophrenia. Neurochemical characteristics that distinguish clozapine from other neuroleptics and contribute to its differential efficacy are not known. We assessed the effects of clozapine on plasma levels of norepinephrine (NE) in a double-blind, parallel groups comparison of clozapine (n = 11) and haloperidol (n = 15) in chronic schizophrenic outpatients who had been previously treated with fluphenazine. Simultaneous measurements were obtained for plasma levels of the catecholamine precursor dopa, the dopamine metabolite dihydroxyphenylacetic acid (DOPAC), the NE metabolite 3,4-dihydroxyphenylglycol (DHPG), adrenocorticotropin (ACTH), cortisol, and hemodynamic parameters. Clozapine produced marked increases (471%) in plasma NE levels, whereas haloperidol had no significant effects on plasma NE levels. Clozapine also increased dopa and tended to increase DOPAC levels, without effects on DHPG, ACTH, or cortisol levels and without consistent changes in blood pressure. Across patients, the magnitude of clozapine-induced increments in plasma NE levels was positively related to improvement in positive symptoms and global symptomatology and was unrelated to the occurrence of extrapyramidal symptoms. The results suggest that clozapine differs importantly from other neuroleptics in increasing plasma NE levels, with the peripheral noradrenergic stimulation related to its superior efficacy profile. The unchanged DHPG levels and absence of hypertension suggest a more complex mechanism of action of clozapine than heightened NE release alone.
NE levels, whereas haloperidol had no significant effects on plasma NE levels. Clozapine also increased dopa and tended to increase DOPAC levels, without effects on DHPG, ACTH, or cortisol levels and without consistent changes in blood pressure. Across patients, the magnitude of clozapine-induced increments in plasma NE levels was positively related to improvement in positive symptoms and global symptomatology and was unrelated to the occurrence of extrapyramidal symptoms. The results suggest that clozapine differs importantly from other neuroleptics in increasing plasma NE levels, with the peripheral noradrenergic stimulation related to its superior efficacy profile. The unchanged DHPG levels and absence of hypertension suggest a more complex mechanism of action of clozapine than heightened NE release alone. [Neuropsychopharmacology 10:1-7, 1994J Clozapine is an atypical neuroleptic with superior anti psychotic efficacy in patients with schizophrenia who are refractory to conventional treatments (Kane et al., 1988; Meltzer et al., 1990; Pickar et al. 1992; Breier et al. 1993) . Intensive investigational efforts are aimed at identifying the biochemical characteristics of clozapine that produce its superior efficacy. This study reports that clozapine produces a striking peripheral neu rochemical profIle, including very high plasma levels of norepinephrine (NE) , and that this profIle is related to clozapine's clinically benefIcial effects.
The neurochemical effects of clozapine differ in sev eral ways from those of conventional neuroleptics. These properties include a high ratio of serotonergic 5-HT2 receptor to dopamine D2 receptor binding (Melt-zer 1989) and relatively high affinity for the newly cloned D4 receptor (Van Tol et al. 1991) . Clozapine also has higher affinity for noradrenergic Ul-and U2-adrenoceptors than do many conventional neurolep tics (Baldessarini and Frankenberg 1991; Cohen and Lipinski 1986; Richelson and Nelson 1984) . In rats, clozapine increases the activity of noradrenergic neu rons and noradrenergic turnover (Baldessarini et al., 1992) . Clinical studies have demonstrated that chronic clozapine treatment increases cerebrospinal fluid (CSF) and plasma NE levels, whereas conventional neurolep tics do not (Pickar et al., 1992; Liberman et al., 1991; Ackenheil 1989) . No study to date has reported a significant relationship between clozapine's noradren ergic effects and its superior clinical efficacy.
The present study used a double-blind, parallel groups design to compare the effects of clozapine with those of haloperidol on plasma levels of NE in patients who had been previously treated with fluphenazine. Plasma levels of dopa, the precursor of the catechola mines; dihydroxyphenylacetic acid (DOPAC), a dopa mine metabolite; 3,4-dihydroxyphenylglycol (DHPG), the intraneuronal metabolite of NE; and hemodynamic parameters were also measured. These indices reflect specific aspects of NE synthesis and metabolism and, therefore, provide information about mechanisms of changes in NE levels. Plasma cortisol and adrenocor ticotropin (ACTH) were measured to assess the spec ificity of noradrenergic effects. Relationships between clozapine's effects on plasma NE levels and symptom ratings were examined.
MATERIALS AND METHODS

Subjects
Twenty-six outpatients of the Maryland Psychiatric Re search Center participated in a double-blind, parallel groups efficacy study of clozapine compared to halo peridol for chronic schizophrenia. The complete admis sion criteria and results of the efficacy study have been reported previously (Breier et al. 1993) . In brief, patients who met DSM III-R (American Psychiatric Association) criteria for chronic schizophrenia as determined by a Structured Clinical Interview for DSM III R (SCID) (Spit zer et al. 1989 ) and by a best-estimate diagnostic con ference led by two research psychiatrists were included in the study. Patients with concurrent drug abuse, al coholism, organic brain disorders, mental retardation, or a medical condition in which clozapine is contrain dicated were excluded from the study of the patients. The age range of the patients was 18 to 55 years. In ad dition, patients had a history of partial responsiveness to conventional neuroleptics and had residual positive and/or negative symptoms at the time of admission to the study. Eleven patients were assigned randomly to receive clozapine and 15 were assigned to receive halo peridol. Their sociodemographic and illness character istics are presented in Table 1 .
Study Design
Patients underwent a 6-week prospective, open-labeled trial of fluphenazine (20 mg/day) to confIrm the pres ence of neuroleptic partial responsiveness and to es tablish clinical stability. Patients were than randomly assigned to either clozapine or haloperidol groups dur ing a 10-week double-blind trial. Haloperidol-assigned patients received a fIxed dose of double-blind cogentin (4 mg/day). Blood was drawn during the last week of fluphenazine treatment (baseline) and after 5 weeks of either clozapine or haloperidol treatment. Pulse rates and blood pressures were obtained at baseline and af ter 5 weeks of treatment. Daily doses of clozapine and haloperidol were increased progressively in a fixed manner to 400 mg/ day and 20 mg/ day, respectively, by the 4th treatment week and were then held constant through the 5th week. Thus, blood was drawn at sta ble doses of comparable potencies of the two drugs. The night before blood sampling, patients abstained from food and drink except water and reported to the clinic between 8:00 AM and 9:00 AM. An intravenous catheter was inserted into the antecubital fossa and kept patent with a heparin lock. After the subjects had been supine (resting) for 75 minutes, blood samples were drawn.
Assaying Procedure
Blood for assays of NE, dopa, DOPAC, and DHPG con centrations was collected in heparinized tubes and im mediately placed on ice, centrifuged within 30 minutes of collection, and the plasma stored at -70°C. Plasma catechol levels were assayed simultaneously using liq uid chromatography with electrochemical detection, as described previously (Eisenhofer et al. 1986 ). Briefly, after addition of an internal standard (dihydroxybenyla mine) to the plasma, the catechols were extracted by absorption on alumina. After elution from the alumina, they were separated by reverse-phase, ion-pairing liq uid chromatography and quantifIed by the current pro duced on exposure of the column effluent to a series of oxidizing electrodes and then a reducing electrode. The limits of detection were approximately 10 pg/ml. Blood for assays of cortisol and ACTH concentrations was collected in ethylenediaminetetraacetic acid-con taining tubes, immediately placed on ice, centrifuged within 30 minutes of collection, and the plasma was stored at -70°C. Cortisol and ACTH levels were as sayed in duplicate by radioimmunoassay (Chrousos et al. 1984) . The approximate limit of detection for ACTH was 1 pg/ml and for cortisol it was 1 Ilg/dl.
Behavioral Assessments
Positive symptoms were assessed using the sum of the following four Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham 1961) items: hallucinations, con ceptual disorganization, suspiciousness, and bizarre thoughts. The sum of the 18-item BPRS (total BPRS scores ranged from 18 to 126) was used as a general mea sure of symptomatology. The instrument was ad ministered by masters and doctoral level clinicians with extensive experience with schizophrenia. Interrater reliability for the BPRS was 0.87. These two measures were selected for this study because they were sig nifIcantly reduced by clozapine in our efficacy study (Breier et al. 1993) and in recent controlled studies (Kane et al. 1988; Pickar et al. 1992 ). In addition, extrapyrami dal symptoms were assessed at baseline and after 10 weeks of treatment, using the Simpson-Angus Scale (scores ranged from 0 to 51) (Simpson and Angus, 1970) .
Statistical Analyses
All plasma indices were fIrst analyzed in a two-factor multivariate analysis of variance (MANOV A) using Hotelling's statistic, with the factors DRUG (clozapine or haloperidol) and TIME (baseline and 5-week treat ment points). If a signifIcant TIME versus DRUG inter action was found, each clozapine versus haloperidol week 5 plasma measure was then analyzed with an analysis of covariance, using baseline plasma levels as the covariate. Effects on physiologic parameters (heart rate, blood pressure) were determined by comparing values at 5 weeks of treatment using baseline (fluphena zine) values as covariates. Five-week treatment minus baseline change values for plasma and physiologic variEffect of Clozapine on Plasma Norepinephrine 3 abIes and 10-week (endpoint) minus baseline change values for BPRS scores and Simpson-Angus scores were calculated and used in correlative analyses.
RESULTS
The MANOV A for all neurochemical data revealed signifIcant effects for DRUG (F = 5.6; df = 6,18; p = .002), TIME (F = 4.9; df = 6,18; p = .004), and DRUG versus TIME interaction (F = 5.1; df = 6,18; p = .003).
Norepinephrine Levels
Plasma NE levels in clozapine-treated patients were al most fIvefold greater than those in the same patients treated with fluphenazine and almost fIvefold greater than in haloperidol-treated patients (Fig. 1) . Haloperidol treatment did not signifIcantly affect plasma NE levels.
Dopa, DOPAC, and DHPG Levels
Clozapine, in comparison to haloperidol, produced signifIcant elevations in plasma dopa levels and tended to increase plasma DOPAC levels (Table 2 ). There were, however, no signifIcant differences between clozapine and haloperidol treatment in plasma DHPG levels (Ta ble 2). Changes in dopa levels during clozapine treat ment were signifIcantly related to changes in NE levels (r = .75, P = .008). Change in NE was not signifIcantly related to change in DOPAC and DHPG.
Cortisol and ACTH Levels
There were no signifIcant differences between cloza pine and haloperidol for plasma cortisol and ACTH lev els (Table 3) . Change in plasma NE was not signifIcantly related to changes in cortisol and ACTH. Figure 1 . The effects of clozapine (n = 11) and haloperidol (n = 15) on plasma NE levels (mean ± 5D). 
Heart Rate and Blood Pressure
There were signifIcant increases in heart rate (beats per minute) produced by clozapine (baseline: 70.2 ± 11 and week 5: 101.8 ± 9), compared with haloperidol (base line: 69.4 ± 15 and week 5: 73.4 ± 10) (F = 62.3; df = 1,20; P < .0001). Systolic blood pressure (mg Hg) was not signifIcantly different between clozapine (baseline: 119 ± 15 and week 5: 120 ± 15) and haloperidol (base line: 122 ± 15 and week 5: 126 ± 13) (F = 1.4; df = 1,20; p = .23). Similarly, diastolic blood pressure was not signifIcantly different between clozapine (baseline: 72 ± 10 and week 5: 76 ± 9) and haloperidol (baseline: 70 ± 7 and week 5: 76 ± 7) (F = 0.4; df = 1,20; p = .5). There were no signifIcant correlations between change on plasma NE and change in heart rate or systolic or di astolic blood pressure.
Norepinephrine and Symptom Changes
Changes in plasma NE levels were signifIcantly cor related with clozapine-related changes in BPRS posi- tive symptom and BPRS total symptom scores ( Figure  2 ). There was no signifIcant relationship between change in NE and change in symptoms during haloperidol treatment. Simpson-Angus scores of extrapyramidal symptoms were low at baseline and after 10 weeks of treatment with clozapine (baseline: 1.5 ± 1 and week 10: 1.6 ± 2.1) or haloperidol (baseline: 1.6 ± 2 and week 10: 2.6 ± 1.8). There was no signifIcant relationship be tween change in Simpson-Angus scores and change in NE levels.
DISCUSSION
The results of this study show that clozapine treatment elicits robust increases in plasma NE levels and that these changes are related to the clinical efficacy of cloza pine in patients with chronic schizophrenia. The fInding of elevated plasma NE levels agrees with previous clinical studies reporting clozapine induced increases in plasma and CSF NE levels in schizophrenic patients (Lieberman et a1. 1991; Pickar et a1. 1992; Ackenheil 1989; Sarafoff et a1. 1979 ). These elevations have been interpreted in terms of increased NE release in the brain and periphery; however, in creased NE release alone cannot easily explain the lack of concurrent increases in plasma levels of OHPG, the main neuronal metabolite of NE, in the present study, and the lack of concurrent increases in CSF levels of MHPG, a major metabolite of NE in the brain, in the study by Pickar et a1. (1992) . Additional possible mech anisms of clozapine-induced increases in NE levels are discussed below. The significant relationship between clozapine's effects on positive and global symptoms and changes in plasma NE levels suggests the possibility that cloza pine's superior efficacy profile results from effects on noradrenergic function in the brain. Although most re search about catecholamines and schizophrenia has fo cused on the pathophysiologic role of dopamine, sev eral lines of evidence from postmortem studies (Farley et a1. 1978; Bird et aI., 1979a Bird et aI., , 1979b Crow et a1. 1979; Kleinman et a1. 1979) or responses to pharmacologic challenges (Sternberg et aI. 1982; Glazer et aI. 1987 ) and CSF and plasma (Breier et a1. 1990; van Kammen et a1. 1989 van Kammen et a1. , 1990 Gomes et a1. 1980; Lake et a1. 1980; Stern berg et a1. 1981; Kemali et a1. 1982; Gattaz et a1. 1983; Castellani et aI. 1982; Naber et aI. 1980; Albus et aI. 1982) have suggested a noradrenergic mechanism. Circulat ing NE does not cross the blood-brain barrier (Leim dorfer et a1. 1947; Liljedahl and Von Euler 1954; Weil Malherbe et aI. 1959) , but drugs that affect NE synthe sis, release, reuptake, metabolism, or adrenoceptor function in the periphery, and which enter the central nervous system, generally produce the same effects in the brain, accounting for directionally similar changes in CSF and plasma NE levels (Goldstein et aI., 1987) .
Treatment with haloperidol and fluphenazine was not associated with plasma NE levels above those nor mally observed in healthy volunteers (Goldstein 1987; Kagedal and Goldstein 1988) . The low rate of extrapy ramidal symptoms and the lack of correlation between these symptoms and NE levels suggests that the rela tionship between improvement in positive symptoms and global symptomatology and change in plasma NE is not secondary to the influences of extrapyramidal symptoms.
Oozapine has high affi nity for the ul-adrenoceptor with three times greater potency at this receptor than haloperidol (Cohen and Lipinski 1986; Richelson and Nelson 1987; Baldessarini and Frankenberg 1991) . In addition, clozapine treatment upregulates u1-adreno ceptors, with particularly marked effects in forebrain areas (Cohen and Lipinski 1986) . In contrast, cloza pine has little effect on dopamine 02 receptor density, whereas haloperidol and other conventional neurolepEffect of Cloza p ine on Plasma Nore p ine p hrine 5 tics upregulate 02 receptors (Cohen and Lipinski 1986) . One may propose that blockade of u1-adrenoceptor mediated effects in the brain is the basis for the clinical benefit of clozapine treatment, and that clozapine induced blockade of u1-adrenoceptors may produce secondary increases in NE release.
Clozapine also antagonizes uz-adrenoceptors (Souto et aI. 1979) . Other neuroleptics bind to this recep tor as well, although neuroleptics generally bind more avidly to U1-than u2-adrenoceptors (Baldessarini et a1. 1992) . In the brain and periphery, u2-adrenoceptor blockade increases NE release, probably by interfering with modulation by u2-adrenoceptors on noradrener gic cells or terminals.
Combined blockade of U1-than u2-adrenoceptors would be expected to produce high plasma NE levels, due to vasodilation-induced reflexive increases in sym pathoneural outflow, combined with the above-noted blockade of modulatory uz-adrenoceptors on sym pathetic nerves. Blockade of U1-and u2-adrenoceptors also helps to explain the lack of increase in blood pres sure in clozapine-treated patients, despite marked in creases in plasma NE levels sufficiently large to evoke vasoconstriction and hypertension in healthy volun teers (Goldstein et a1. 1986 ).
This mechanism of increases in NE levels cannot explain, however, the lack of increase in OHPG levels in the present study, because both reflexive stimula tion of sympathetic outflow and blockade of u2-adreno ceptors increases reuptake of endogenously released NE. Analogously, clozapine has been reported not to aff ect CSF MHPG levels, despite significant increases in CSF NE levels (Pickar et a1. 1992) . The latter finding excludes augmented O-methylation as the basis for the lack of increase in OHPG levels.
These unexpected results force consideration of other mechanisms by which clozapine may increase NE concentrations in extracellular fluid in the brain and pe riphery without concurrent increases in concentrations of its neuronal metabolite. The most straightforward additional mechanism is blockade of NE reuptake. The combination of reuptake blockade and u2-adrenoceptor blockade produces marked increases in plasma NE lev els in healthy volunteers (Goldstein et a1. 1986 (Goldstein et a1. , 1988 . Because blood pressure also increases acutely in this setting, combined reuptake blockade and uz-adreno ceptor blockade would not account for the hemodynamic data. The combination of high plasma NE levels, the absence of changes in OHPG levels, and the absence of hypertension during clozapine treatment therefore seem to require a complex mechanism that includes blockade of both subtypes of u-adrenoceptors and block ade of the NE transporter. We are unaware of research findings testing the latter putative effect of clozapine. The increases in plasma OOP A and OOPAC levels are consistent with increased catecholamine biosynthesis in sympathetic nerves, to match increases in noradren-ergic turnover. Analogous changes in DOPA and DOPAC levels have been reported in noradrenergic centers in the brain in animals undergoing clozapine treatment (Baldessarini et al. 1992 ). It will be important to exam ine the time course of clozapine's effects on noradrener gic function to determine if data gleaned from acute dos ing studies apply to chronic treatment conditions.
The failure of clozapine to change plasma ACTH and cortisol levels supports the contention that the ele vations in plasma NE levels are not secondary to gener alized arousal or distress. Previous clinical studies have reported that chronic clozapine treatment decreases plasma cortisol levels (Pickar et al. 1992; Meltzer 1989) . It is possible that reductions in cortisol previously ob served were secondary to clozapine's effects on reduc ing stress and arousal, compared with levels in the un treated control condition. Because our subjects were stable outpatients and did not participate in neurolep tic washout (which may increase arousal, activation and stress) prior to clozapine treatment, they would have been less likely to experience stress-reducing effects from clozapine.
In summary, clozapine treatment markedly in creases plasma NE levels, with the increases related to clinical effects of the drug. The mechanism of noradren ergic activation appears to be complex, possibly involv ing a combination of adrenoceptor blockade and block ade of the NE transporter. The fIndings generally lead one to reconsider the role of endogenous NE in the pathophysiology of schizophrenia, with central nor adrenergic systems a potential new target of antipsy chotic drug action.
